After Covid, BioNTech Has Its Sights Set on Malaria

104
18
Favorite

After Covid, BioNTech Has Its Sights Set on Malaria

Motley Fool2021-07-27

BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

104

Report

Comment（18）

KVCGTan
·2021-07-27
Interesting. Like?
Reply
1
Report
Lsn
·2021-07-27
Good ?
Reply
2
Report
Fold Replies
- sarahlovesgh:
  Nice
  2021-07-27
  Reply
  Report
PengsieX
·2021-07-27
Please check on mRNA long term side effects first
Reply
2
Report
虎视Tan
·2021-07-27
Good move why not set sight on dengue
Reply
3
Report
XavierSee
·2021-07-27
Nice
Reply
Like
Report
Archiparia
·2021-07-27
I think biontech stock will rise a lot
Reply
Like
Report
Ferocious
·2021-07-27
That’s something positive
Reply
Like
Report
Eddie318
·2021-07-27
Awesome news
Reply
1
Report
MrInvestor
·2021-07-27
Gogogo
Reply
1
Report
Fold Replies
- Dittosg:
  upupup
  2021-07-27
  Reply
  Report
WW1012
·2021-07-27
Great news
Reply
4
Report
Fold Replies
- WW1012:
  Bull bull
  2021-07-27
  Reply
  Report
georgiahobo
·2021-07-27
good
Reply
4
Report
Fold Replies
- JosephPeh:
  hahaha
  2021-07-27
  Reply
  Report
- JadynY:
  ??
  2021-07-27
  Reply
  Report
- Elishaaa:
  Gsk
  2021-07-27
  Reply
  Report
NgKenny
·2021-07-27
Good
Reply
3
Report
Fold Replies
- GANCL:
  Yes
  2021-07-27
  Reply
  Report
Ktkw
·2021-07-27
Aure
Reply
2
Report
MikeSeah
·2021-07-27
Commend
Reply
5
Report
CharlesKing
·2021-07-27
Like and comment plz???
Reply
7
Report
MightyPooP
·2021-07-27
Don't we already have malaria pills?
Reply
3
Report
ARIESan
·2021-07-27
Finally ?????
Reply
4
Report
russ1122
·2021-07-27
hi
Reply
3
Report
Fold Replies
- russ1122:
  hi
  2021-07-27
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1153403036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-27 11:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153403036","market":"us","top_or_hot":-1,"title":"After Covid, BioNTech Has Its Sights Set on Malaria","media":"Motley Fool","content":"<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","article_id":"1153403036","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","pubTimestamp":1627356038,"sourceInfo":null,"weMediaInfo":null,"summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"在Covid之后，BioNTech将目光投向了疟疾","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9},"content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":809683583,"gmtCreate":1627365544142,"gmtModify":1703488458482,"author":{"id":"3570938362108330","authorId":"3570938362108330","authorIdStr":"3570938362108330","name":"KVCGTan","avatar":"https://static.tigerbbs.com/2126be6bc046089345232547cb51d38a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570938362108330"},"htmlText":"Interesting. Like?","listText":"Interesting. Like?","text":"Interesting. Like?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809683583","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809698424,"gmtCreate":1627363186168,"gmtModify":1703488418753,"author":{"id":"3586853455165770","authorId":"3586853455165770","authorIdStr":"3586853455165770","name":"Lsn","avatar":"https://static.tigerbbs.com/b2f8105b7bbd2252317e8eb58f208fc6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586853455165770"},"htmlText":"Good ?&nbsp;","listText":"Good ?&nbsp;","text":"Good ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809698424","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5343270,"gmtCreate":1627363238954,"gmtModify":1663231556945,"authorId":3581734886041988,"author":{"id":3581734886041988,"authorId":3581734886041988,"name":"sarahlovesgh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809698424,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":809690272,"gmtCreate":1627362822096,"gmtModify":1703488411254,"author":{"id":"3578047933589423","authorId":"3578047933589423","authorIdStr":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","vip":2,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":3,"crmLevelSwitch":0,"idStr":"3578047933589423"},"htmlText":"Please check on mRNA long term side effects first","listText":"Please check on mRNA long term side effects first","text":"Please check on mRNA long term side effects first","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809690272","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809609826,"gmtCreate":1627362099165,"gmtModify":1703488398209,"author":{"id":"3581738832645942","authorId":"3581738832645942","authorIdStr":"3581738832645942","name":"虎视Tan","avatar":"https://static.tigerbbs.com/b8937bd48ee9805c92670bd1c3dd8e06","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581738832645942"},"htmlText":"Good move why not set sight on&nbsp;dengue","listText":"Good move why not set sight on&nbsp;dengue","text":"Good move why not set sight on dengue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809609826","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809600385,"gmtCreate":1627362014147,"gmtModify":1703488396580,"author":{"id":"3586581180889843","authorId":"3586581180889843","authorIdStr":"3586581180889843","name":"XavierSee","avatar":"https://static.tigerbbs.com/eb0e623ff55f8e13ab98c063c20cfdb7","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3586581180889843"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809600385","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809875869,"gmtCreate":1627361799251,"gmtModify":1703488392649,"author":{"id":"3582928483660659","authorId":"3582928483660659","authorIdStr":"3582928483660659","name":"Archiparia","avatar":"https://static.tigerbbs.com/f8cc7fc40996c719dfef5dc0edc1819b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582928483660659"},"htmlText":"I think biontech stock will rise a lot","listText":"I think biontech stock will rise a lot","text":"I think biontech stock will rise a lot","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809875869","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809878322,"gmtCreate":1627361509266,"gmtModify":1703488388257,"author":{"id":"3586857174644620","authorId":"3586857174644620","authorIdStr":"3586857174644620","name":"Ferocious","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586857174644620"},"htmlText":"That’s something positive&nbsp;","listText":"That’s something positive&nbsp;","text":"That’s something positive","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809878322","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809879591,"gmtCreate":1627361387413,"gmtModify":1703488384217,"author":{"id":"3575110265749823","authorId":"3575110265749823","authorIdStr":"3575110265749823","name":"Eddie318","avatar":"https://static.tigerbbs.com/64935bcbea3cb0f19632a043b5c4f663","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575110265749823"},"htmlText":"Awesome news","listText":"Awesome news","text":"Awesome news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809879591","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809848179,"gmtCreate":1627360695391,"gmtModify":1703488373149,"author":{"id":"3586672191897597","authorId":"3586672191897597","authorIdStr":"3586672191897597","name":"MrInvestor","avatar":"https://static.tigerbbs.com/40974a38cd623c0089adf8fd12d91591","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586672191897597"},"htmlText":"Gogogo","listText":"Gogogo","text":"Gogogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809848179","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342971,"gmtCreate":1627360803482,"gmtModify":1663231556827,"authorId":3576934932610535,"author":{"id":3576934932610535,"authorId":3576934932610535,"name":"Dittosg","avatar":"https://static.tigerbbs.com/1b2cff59f82218916755d7d3ff0253b2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809848179,"type":1,"supId":0,"prevId":0,"content":"upupup","text":"upupup","html":"upupup"}],"langContent":"EN"},{"id":809848313,"gmtCreate":1627360687732,"gmtModify":1703488372987,"author":{"id":"3553224628095486","authorId":"3553224628095486","authorIdStr":"3553224628095486","name":"WW1012","avatar":"https://static.tigerbbs.com/f992cdfebad899a930707fdd9a236024","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3553224628095486"},"htmlText":"Great news","listText":"Great news","text":"Great news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809848313","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342953,"gmtCreate":1627360697431,"gmtModify":1663231553736,"authorId":3553224628095486,"author":{"id":3553224628095486,"authorId":3553224628095486,"name":"WW1012","avatar":"https://static.tigerbbs.com/f992cdfebad899a930707fdd9a236024","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809848313,"type":1,"supId":0,"prevId":0,"content":"Bull bull","text":"Bull bull","html":"Bull bull"}],"langContent":"EN"},{"id":809857383,"gmtCreate":1627360241942,"gmtModify":1703488367963,"author":{"id":"3584417828671237","authorId":"3584417828671237","authorIdStr":"3584417828671237","name":"georgiahobo","avatar":"https://static.tigerbbs.com/d3d78a5b4a2c30f82d72cb73d5dc3ecd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584417828671237"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/809857383","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5345437,"gmtCreate":1627379269863,"gmtModify":1663231567731,"authorId":3572753777456340,"author":{"id":3572753777456340,"authorId":3572753777456340,"name":"JosephPeh","avatar":"https://static.tigerbbs.com/62ca1442eaf659081bf647e4f3ff4eb0","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809857383,"type":1,"supId":0,"prevId":0,"content":"<u>hahaha</u>","text":"<u>hahaha</u>","html":"<u>hahaha</u>"},{"id":5342950,"gmtCreate":1627360651084,"gmtModify":1663231556436,"authorId":4087899430188250,"author":{"id":4087899430188250,"authorId":4087899430188250,"name":"JadynY","avatar":"https://static.tigerbbs.com/d39e159a365bae2e9344addcdc09e350","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809857383,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"},{"id":5342941,"gmtCreate":1627360582710,"gmtModify":1663231554929,"authorId":4090060794789300,"author":{"id":4090060794789300,"authorId":4090060794789300,"name":"Elishaaa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809857383,"type":1,"supId":0,"prevId":0,"content":"Gsk","text":"Gsk","html":"Gsk"}],"langContent":"EN"},{"id":809858531,"gmtCreate":1627359966823,"gmtModify":1703488361297,"author":{"id":"3582778356971864","authorId":"3582778356971864","authorIdStr":"3582778356971864","name":"NgKenny","avatar":"https://static.tigerbbs.com/4fdae3e0bdca8d3a33e7f9d619f0dc88","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3582778356971864"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809858531","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342926,"gmtCreate":1627360452815,"gmtModify":1663231554937,"authorId":3566524239552357,"author":{"id":3566524239552357,"authorId":3566524239552357,"name":"GANCL","avatar":"https://static.tigerbbs.com/02bdb0309baf16b47e74509dc75824e6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809858531,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":809853042,"gmtCreate":1627359763986,"gmtModify":1703488356879,"author":{"id":"3564917665277560","authorId":"3564917665277560","authorIdStr":"3564917665277560","name":"Ktkw","avatar":"https://static.tigerbbs.com/c3b319f06c5f5672546acc9d6f02dec1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3564917665277560"},"htmlText":"Aure","listText":"Aure","text":"Aure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809853042","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809815573,"gmtCreate":1627357555092,"gmtModify":1703488309074,"author":{"id":"4087643331353810","authorId":"4087643331353810","authorIdStr":"4087643331353810","name":"MikeSeah","avatar":"https://static.tigerbbs.com/af89cc80b93afeea040648878fda3a52","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087643331353810"},"htmlText":"Commend","listText":"Commend","text":"Commend","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809815573","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809839376,"gmtCreate":1627356529295,"gmtModify":1703488286457,"author":{"id":"3579391265651951","authorId":"3579391265651951","authorIdStr":"3579391265651951","name":"CharlesKing","avatar":"https://static.tigerbbs.com/d8fbdcf3295ba7f84c1f2205610ea968","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579391265651951"},"htmlText":"Like and comment plz???","listText":"Like and comment plz???","text":"Like and comment plz???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809839376","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809894457,"gmtCreate":1627356380079,"gmtModify":1703488282686,"author":{"id":"3575163551534398","authorId":"3575163551534398","authorIdStr":"3575163551534398","name":"MightyPooP","avatar":"https://static.tigerbbs.com/aec66d00ca2b1f2b75412008d93edd14","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":1,"idStr":"3575163551534398"},"htmlText":"Don't we already have malaria pills?","listText":"Don't we already have malaria pills?","text":"Don't we already have malaria pills?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809894457","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809896670,"gmtCreate":1627356245690,"gmtModify":1703488277800,"author":{"id":"4087545408973980","authorId":"4087545408973980","authorIdStr":"4087545408973980","name":"ARIESan","avatar":"https://static.tigerbbs.com/ab7b9364a4791173d66fbb5fda8ef925","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087545408973980"},"htmlText":"Finally ?????","listText":"Finally ?????","text":"Finally ?????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809896670","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":809898946,"gmtCreate":1627356146985,"gmtModify":1703488275850,"author":{"id":"3566449916340164","authorId":"3566449916340164","authorIdStr":"3566449916340164","name":"russ1122","avatar":"https://static.tigerbbs.com/410e5ecfb4da8e3f85caaaf9808925f2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566449916340164"},"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809898946","repostId":1153403036,"repostType":4,"repost":{"id":"1153403036","pubTimestamp":1627356038,"share":"https://ttm.financial/m/news/1153403036?lang=&edition=fundamental","pubTime":"2021-07-27 11:20","market":"us","language":"en","title":"After Covid, BioNTech Has Its Sights Set on Malaria","url":"https://stock-news.laohu8.com/highlight/detail?id=1153403036","media":"Motley Fool","summary":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little mor","content":"<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.</p>\n<p>On Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.</p>\n<p>The Hardest Pathogen to Hack</p>\n<p>There is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.</p>\n<p>BioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:</p>\n<ul>\n <li>One such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.</li>\n <li>BioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.</li>\n</ul>\n<p>\"This will not be a home run,\" Şahin told the<i>Financial Times</i>. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.</p>\n<p><b>Invasive And Evasive:</b>Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After Covid, BioNTech Has Its Sights Set on Malaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter Covid, BioNTech Has Its Sights Set on Malaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/26/after-covid-biontech-has-its-sights-set-on-malaria/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153403036","content_text":"BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is world-famous for creating one of the most successful coronavirus vaccines, its shares are up 150%, and co-founder Uğur Şahin is now one of the world's 500 richest people. Not too shabby.\nOn Monday, the company announced its next quest: a solo venture to develop a shot that will prevent malaria, one of the world's deadliest diseases and a notorious enigma for vaccine producers.\nThe Hardest Pathogen to Hack\nThere is currently only one approved malaria vaccine. Mosquirix, developed by GlaxoSmithKline, is only 39% effective over four years. Meanwhile, there were 229 million malaria cases in 2019 — 94% of them in Africa — and 400,000 people die from the disease every year, almost all of them African children.\nBioNTech will develop malaria vaccine candidates using messenger ribonucleic acid (mRNA), which directs the body to make parts of a virus to provoke an immune response. The firm will also produce and test other candidates at facilities in Africa:\n\nOne such candidate, the first shot to clear the World Health Organization's 75% efficacy target, was introduced this year by the University of Oxford. It prevented 77% of cases in a study of 450 children in Burkina Faso, and a 4,800-child trial to confirm the results is in the planning stages.\nBioNTech is aiming to have mRNA malaria and tuberculosis vaccines ready for clinical trials next year, but said malaria could prove as difficult to research as cancer. The company has benchmarked €20 million to €50 million for early stage development.\n\n\"This will not be a home run,\" Şahin told theFinancial Times. \"This is a pathogen which is really, really difficult to hack.\" Any malaria vaccine BioNTech develops will be sold in Africa on a non-profit basis, and the company is aiming for a shot that's 90% effective for one to two years.\nInvasive And Evasive:Malaria is caused by a complex parasite that can potentially make thousands of antigens and has many methods of evading the immune system. Unlike many diseases, it's possible to catch again and again due to its complexity.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5342332,"gmtCreate":1627356155022,"gmtModify":1663231552528,"authorId":3566449916340164,"author":{"id":3566449916340164,"authorId":3566449916340164,"name":"russ1122","avatar":"https://static.tigerbbs.com/410e5ecfb4da8e3f85caaaf9808925f2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":809898946,"type":1,"supId":0,"prevId":0,"content":"hi","text":"hi","html":"hi"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":104,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}